ESCHER-GROUP
9.10.2018 07:12:12 CEST | Business Wire | Press release
Post-Expo 2018, Booth #B1.360 – Escher Group , the company transforming the postal and courier market with their innovative customer engagement platform, today announced that Nick Manolis has been named chief executive officer (CEO) of Escher, and that he has also been appointed to the company’s board of directors. For more than two decades, postal operators and couriers have relied on Escher to improve their customer experience at all points of engagement, accelerate service delivery and help them to transform their business to a more efficient variable cost model in a budget-constrained world. Escher has emerged as the worldwide market leader in customer engagement solutions for postal point-of-service (POS), and Manolis will be responsible for leading the company’s continued global expansion.
“Nick is a proven executive in leading high-performing, customer-centric technology companies,” said Matthew Peacock, founding partner at Hanover and Escher board member. “That talent combined with his success in innovating global retail platform solutions makes him a perfect fit to lead Escher as the company looks to expand its reach globally into new countries, and postal and courier markets.”
Outdated IT infrastructure and antiquated operating models no longer work for postal operators and couriers who need to manage the growth of parcels and adapt to today’s digitally savvy customers who want to be engaged on their own terms. Forward-looking postal executives are investing in customer engagement platforms to provide the best customer experience, increase revenues and move to a variable cost model.
With its unique and purpose-built customer engagement platform, Escher enables postal operators to shift to modern and profitable customer engagement strategies that embrace today’s digitally disruptive world. With new and deeper points of engagement – including third-party locations, kiosks, expanded pick-up drop-off (PUDO) locations and mobile point of sale – Escher makes it easier for postal customers to do business. Escher drives efficiency by automating and streamlining business processes and easily operationalizing new points of engagement. New services can be rolled out in days and third-party services can be implemented overnight.
With 25 unique post-centric technology patents, Escher has been able to deploy more than 350 thousand customer engagement points globally, which has resulted in more than two billion transactions processed annually. Escher has transformed how 35 postal operators around the globe profitably interact with their customers.
“Postal operators and couriers worldwide rely on Escher as they make the shift to a modern and profitable customer engagement strategy and embrace today’s digitally disruptive world. Our platform allows them to rapidly deliver new services and capabilities, while also providing a superior customer experience. With Escher, postal executives can do more with the resources with which they are entrusted,” said Nick Manolis. “I am honored to work with the exceptional team at Escher and the posts we serve globally.”
Manolis has spent the last ten years at TrueCommerce, a global provider of retail trading partner connectivity and integration solutions, as president and CEO. Under Manolis’ leadership, TrueCommerce provided a global trading platform that connected 12,000 suppliers with nearly 92,000 retailers worldwide.
Meet Manolis and the Escher team, and learn more about Escher’s customer engagement platform at Post-Expo booth #B1.360.
About Escher
Escher is transforming postal operators and couriers worldwide, enabling them to engage today’s digitally savvy customers across all points of engagement. With Escher’s unique, purpose-built customer engagement platform, posts can drive superior customer experience, with greater speed and better economics. Learn more: www.eschergroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005847/en/
Contact:
Media Contact 280blue, Inc. Amanda McKinney amanda@280blue.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom